Director/PDMR Shareholding

Director/PDMR Shareholding March 3, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announcesthat on February 28, 2014, Stock Appreciation Rights ("SARs") and PerformanceShare Awards ("PSAs") were granted to Persons Discharging ManagerialResponsibility ("PDMRs") under Part A and Part B respectively of The ShirePortfolio Share Plan ("PSP"). SARs and PSAs will normally vest after threeyears, subject to any performance conditions being satisfied, with noconsideration payable on these awards. The awards were granted over notionalOrdinary Shares ("Shares") and American Depositary Shares ("ADSs") in theCompany as follows: PDMR Type of Award Type of Number of Exercise Price (1) Security(2) Securities Flemming Ornskov SAR ADS 34,174 $168.54 PSA ADS 25,631 Nil Tatjana May SAR Share 26,718 £33.83 PSA Share 22,329 Nil 1. SARs and PSAs granted to Dr. Ornskov and PSAs granted to Ms. May are subject to performance conditions. 2. One ADS is equal to three Shares. The Company also announces that PSAs granted to PDMRs on February 28, 2011under Part B of the PSP vested on February 28, 2014. The number of Sharesreleased and the number of Shares sold to satisfy personal tax liabilities wereas follows: PDMR Shares Released(3) Shares Sold(4) Graham Hetherington(5) 61,689 29,287 Tatjana May 20,742 9,848 3. In accordance with the PSP rules, the vested PSAs have been increased to reflect the dividends paid by the Company during the period from the date of grant to the date of vesting. 4. Shares were sold on the London Stock Exchange at an average sale price of £ 33.98 each. 5. The PSA granted to Graham Hetherington was subject to performance conditions measured over the performance period 2011 to 2013. Based on the performance conditions, 100% of the PSA vested. This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules. Tony Guthrie Deputy Company Secretary For further information please contact: Investor Relations Laurie Stelzer [email protected] +1 781 482 0733 Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 Notes to editors Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal andInternal Medicine and we are developing treatments for symptomatic conditionstreated by specialist physicians in other targeted therapeutic areas. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com